'There's a lot of momentum': Biogen acquisition led to new West Coast hub

"HI-Bio was really the key catalyst to bring us back to California," a Biogen executive said of its new South San Francisco ...
The Business Journals

Biotech pioneer who helped launch Biogen dies at 94

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Charles Weissmann's ...

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug ...
Fierce Biotech

Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody

Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...
FierceBiotech

Biogen beefs up immunology pipeline with $1B deal for Vanqua's preclinical C5aR1 antagonist

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...
FiercePharma

Biogen looks to shake up SMA status quo with FDA nod for high-dose version of Spinraza

After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market.
Business Wire

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...
24/7 Wall St.

UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Biogen (NASDAQ:BIIB | BIIB Price Prediction) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst ...
STAT

Biogen to acquire immunology biotech Apellis for $5.6 billion

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Biogen said Tuesday that ...